Ontology highlight
ABSTRACT: Purpose
Metformin has been the first-line treatment for type 2 diabetes mellitus as monotherapy or concomitantly with other glucose-lowering therapies due to its efficacy, safety, and affordability. Recent studies on the cardioprotective and renoprotective benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) have influenced guidelines on diabetes management to consider these newer agents as alternative first-line therapies. This paper explores the literature supporting the use of these newer medications alone as a first-line agent in place of metformin.Methods
A review of citations from the most recent guidelines along with a literature search via PubMed was completed to review (1) what, historically, made
SUBMITTER: Andraos J
PROVIDER: S-EPMC11196467 | biostudies-literature | 2024 Jun
REPOSITORIES: biostudies-literature